CD38 and plasma cell myeloma: Initial treatment with daratumumab (DARA), an anti-CD38 MoAb, in combination with PIs or IMiDs as initial therapy in transplant-naïve patients prolonged progression-free survival (PFS) and overall survival (OS) compared with those after conventional standard therapy in phase III ALCYONE and MAIA studies on transplant-ineligible newly diagnosed myeloma [1,2].